Xanthines as Adenosine Receptor Antagonists

作者: Christa E. Müller , Kenneth A. Jacobson

DOI: 10.1007/978-3-642-13443-2_6

关键词:

摘要: The natural plant alkaloids caffeine and theophylline were the first adenosine receptor (AR) antagonists described in literature. They exhibit micromolar affinities are non-selective. A large number of derivatives analogues subsequently synthesized evaluated as AR antagonists. Very potent have thus been developed with selectivity for each four subtypes.

参考文章(241)
S M Weiss, L J Knutsen, KW-6002 (Kyowa Hakko Kogyo). Current opinion in investigational drugs. ,vol. 2, pp. 668- 673 ,(2001)
R. F. Bruns, G. H. Lu, T. A. Pugsley, Adenosine Receptor Subtypes: Binding Studies Topics and Perspectives in Adenosine Research. pp. 59- 73 ,(1987) , 10.1007/978-3-642-45619-0_6
Cirillo R, Barone D, Franzone Js, Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Archives internationales de pharmacodynamie et de thérapie. ,vol. 295, pp. 221- 237 ,(1988)
Andreas Bauer, Kiichi Ishiwata, Adenosine Receptor Ligands and PET Imaging of the CNS Adenosine Receptors in Health and Disease. ,vol. 193, pp. 617- 642 ,(2009) , 10.1007/978-3-540-89615-9_19
Dieter Ukena, Kenneth A. Jacobson, Kenneth L. Kirk, John W. Daly, A [3 H]amine congener of 1,3-dipropyl-8-phenylxanthine FEBS Letters. ,vol. 199, pp. 269- 274 ,(1986) , 10.1016/0014-5793(86)80493-8
H. Markus Weiß, Reinhard Grisshammer, Purification and characterization of the human adenosine A2a receptor functionally expressed in Escherichia coli European Journal of Biochemistry. ,vol. 269, pp. 82- 92 ,(2002) , 10.1046/J.0014-2956.2002.02618.X
Kenneth A. Jacobson, Probing Adenosine Receptors Using Biotinylated Purine Derivatives Methods in Enzymology. ,vol. 184, pp. 668- 671 ,(1990) , 10.1016/0076-6879(90)84333-C
Kenneth A. Jacobson, Gary L. Stiles, A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. Molecular Pharmacology. ,vol. 32, pp. 184- 188 ,(1987)
Sheila A Doggrell, BG-9928 (Biogen Idec). Current opinion in investigational drugs. ,vol. 6, pp. 962- 968 ,(2005)